Key Decisions in HIV Care

Learn how to initiate PrEP in underserved communities, with examples on overcoming barriers and improving access.

Latesha Elopre, MD, MSPH Released: June 7, 2021

Download this PDF to share with your patients who are interested in HIV pre-exposure prophylaxis

Jason Schafer, PharmD, MPH Released: February 24, 2022

Listen as Latesha Elopre, MD, MSPH, explains how to initiate PrEP in underserved communities, with examples on overcoming barriers and improving access.

Latesha Elopre, MD, MSPH Released: July 7, 2021

See how to initiate PrEP in underserved communities, with examples on overcoming barriers and improving access.

Latesha Elopre, MD, MSPH Released: June 7, 2021

In this case example, learn the data to support LA PrEP including both efficacy and safety data from the major clinical trials that led to the approval of cabotegravir for PrEP.

Jason Schafer, PharmD, MPH Released: February 8, 2022

Learn the data to support LA PrEP including both efficacy and safety data from the major clinical trials that led to the approval of cabotegravir for PrEP.

Jason Schafer, PharmD, MPH Released: February 16, 2022

Listen as Jason Schafer, PharmD, MPH, shares the latest data to support long-acting PrEP, including efficacy and safety data from the major clinical trials that led to the approval of cabotegravir for PrEP.

Jason Schafer, PharmD, MPH Released: March 14, 2022

As a gay man who is also a physician, I am considering long-acting PrEP but have many questions about how it would work in my life.

Anonymous Patient Released: February 3, 2022

Important considerations for PrEP in transgender individuals include choosing the right PrEP option and addressing stigma to improve adherence.

Karine Lacombe, MD, PhD Released: April 15, 2022

Adherence and accessibility are critical to improving uptake and effectiveness of PrEP for PWID.

Karine Lacombe, MD, PhD Released: April 15, 2022

In this case example, learn some of the key considerations for using long-acting injectable cabotegravir for PrEP including management of missed dosing, stopping PrEP, and screening for HIV while on PrEP.

Jason Schafer, PharmD, MPH Released: February 16, 2022

Listen as Jason Schafer, PharmD, MPH, shares key considerations for using long-acting injectable cabotegravir for PrEP, including management of missed dosing, stopping PrEP, and screening for HIV while receiving PrEP.

Jason Schafer, PharmD, MPH Released: March 21, 2022

Learn some of the key considerations for using long-acting injectable cabotegravir for PrEP including management of missed dosing, stopping PrEP, and screening for HIV while on PrEP.

Jason Schafer, PharmD, MPH Released: March 15, 2022

In this on-demand recording of a live webinar, expert faculty review key considerations for the use of PrEP in cisgender women. Topics include current data and recommendations for the use of oral and long-acting injectable PrEP options.

Latesha Elopre, MD, MSPH Karine Lacombe, MD, PhD Released: March 24, 2022

Learn key considerations for the use of PrEP in cisgender women. Topics include current data and recommendations for the use of oral and long-acting injectable PrEP options.

Latesha Elopre, MD, MSPH Karine Lacombe, MD, PhD Released: February 15, 2022

Learn key considerations for the use of PrEP in cisgender men and transgender women. Topics include current data and recommendations for the use of oral and long-acting injectable PrEP options.

Latesha Elopre, MD, MSPH Karine Lacombe, MD, PhD Released: February 15, 2022

In this on-demand recording of a live webinar, expert faculty review key considerations for the use of PrEP in cisgender men and transgender women. Topics include current data and recommendations for the use of oral and long-acting injectable PrEP options.

Latesha Elopre, MD, MSPH Karine Lacombe, MD, PhD Released: March 25, 2022

Australian study shows overwhelming demand and uptake of PrEP and highlights the power of partnering among government, clinical, and academic institutions.

Don Smith, MD Released: March 18, 2022

In this case example, learn data and recommendations for HIV postexposure prophylaxis, including currently recommended regimens, single tablet regimens, and PrEP following PEP.

Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS Released: April 26, 2022

Learn data and recommendations for HIV postexposure prophylaxis, including currently recommended regimens, single tablet regimens, and PrEP following PEP.

Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS Released: April 29, 2022

Listen as Dr Michelle D. Collins-Ogle shares data and recommendations for HIV PEP, including currently recommended regimens, single-tablet regimens, and pre-exposure prophylaxis following PEP.

Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS Released: May 26, 2022

Learn key considerations when selecting a new ART regimen for patients with viral suppression who need a change in HIV treatment. Topics include weighing the pros and cons of switching to contemporary 3-drug therapy regimens, oral 2-drug options, and long-acting injectable 2-drug regimens.

Daniel R. Kuritzkes, MD Chloe Orkin, MBChB, FRCP, MD Released: June 7, 2021

In this on-demand recording of a live webinar, expert faculty discuss important considerations when switching ART in patients with viral suppression on their current regimen, including guideline recommendations and data supporting different switch regimen options such as single-tablet triple therapy, 2-drug oral regimens, doravirine-based regimens, and long-acting injectable therapy.

Daniel R. Kuritzkes, MD Chloe Orkin, MBChB, FRCP, MD Released: June 10, 2021

In this concise presentation, Dr. Daniel Kuritzkes discusses recent data on new long-acting injectable ART.

Daniel R. Kuritzkes, MD Released: May 19, 2021

See key clinical trial data and practical insights such as how to initiate a patient on long-acting therapy, recommended dosing regimens, and factors that may increase the risk of treatment failure.

Daniel R. Kuritzkes, MD Released: June 4, 2021

Listen as Daniel R. Kuritzkes, MD, explains key clinical trial data and gives practical insights such as how to initiate a patient on long-acting therapy, recommended dosing regimens, and factors that may increase the risk of treatment failure.

Daniel R. Kuritzkes, MD Released: July 7, 2021

Learn why one patient feels that long-acting ART gave her a lot of her life back.

Anonymous Patient Released: September 16, 2021

In this case example, learn how to manage planned and unplanned missed CAB plus RPV LA injections according to the FDA label and pharmacokinetic modeling.

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP Released: October 4, 2021

Learn how to manage planned and unplanned missed CAB plus RPV LA injections according to the FDA label and pharmacokinetic modeling.

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP Released: October 4, 2021

Listen as Milena Murray, PharmD, MSc, BCIDP, AAHIVP, shares how to manage planned and unplanned missed CAB plus RPV LA injections according to the FDA label and pharmacokinetic modeling.

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP Released: October 13, 2021

In this case example, learn the data to help you determine when switching to 2-drug single tablet regimens may be warranted.

William R. Short, MD, MPH, AAHIVS Released: September 28, 2021

Learn the data to help you determine when switching to 2-drug single tablet regimens may be warranted

William R. Short, MD, MPH, AAHIVS Released: September 30, 2021

Listen as William R. Short, MD, MPH, AAHIVS, discusses the data to help you determine when switching to 2-drug single-tablet regimens may be warranted.

William R. Short, MD, MPH, AAHIVS Released: November 10, 2021

I was hesitant to switch, but I asked my doctor a million and one questions because I think that taking an active role in your own health and being informed helps ensure you are getting the best care possible.

Anonymous Patient Released: September 27, 2021

Long-acting regimens do not contain HBV active agents, and therefore, it is vital to assess an individual's hepatitis B status before switching.

Prof Gail Matthews, MD, PhD Released: January 25, 2022

In this case example, learn the data on which patient factors may predict failure to LA CAB + RPV and who is and who is not a good candidate for this new treatment option

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP Released: November 24, 2021

Listen as Milena Murray, PharmD, MSc, BCIDP, AAHIVP, shares the latest data about which patient factors may predict failure to LA CAB plus RPV and who is and who is not a good candidate for this new treatment option.

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP Released: December 16, 2021

Learn the data on which patient factors may predict failure to LA CAB + RPV and who is and who is not a good candidate for this new treatment option

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP Released: December 1, 2021

In this case example, learn whether weight gain should or should not be a factor in determining initial therapy.

Joseph J. Eron, Jr., MD Released: July 22, 2021

See whether weight gain should or should not be a factor in determining initial therapy.

Joseph J. Eron, Jr., MD Released: August 2, 2021

Listen as Joseph J. Eron, Jr., MD, explores whether weight gain should or should not be a factor in determining initial therapy.

Joseph J. Eron, Jr., MD Released: August 30, 2021

In this case example, learn the importance of timely initiation of ART for an adolescent patient.

Jason Halperin, MD, MPH Released: September 10, 2021

Learn the importance of timely initiation of ART for an adolescent patient

Jason Halperin, MD, MPH Released: September 24, 2021

Listen as Jason Halperin, MD, MPH, and his patient share their perspectives on whether to rapidly initiate ART for adolescent patients.

Jason Halperin, MD, MPH Released: September 23, 2021

My advice for other young people with HIV is just to start medications and be honest with yourself. You’ll feel much better knowing you’re doing something about it now rather than waiting.

Anonymous Patient Released: September 7, 2021

In this case example, learn the importance of initiation of treatment for OUD along with ART initiation

Jason Halperin, MD, MPH Released: September 10, 2021

Learn the importance of initiation of treatment for OUD along with ART initiation

Jason Halperin, MD, MPH Released: September 24, 2021

Listen as Jason Halperin, MD, MPH, and his patient share their perspectives on why it’s important to rapidly initiate ART and provide treatment for OUD at the same time.

Jason Halperin, MD, MPH Released: September 23, 2021

Learn why addressing OUD along with ART is such an important key decision in HIV care.

Anonymous Patient Released: September 8, 2021

The STAT study suggests we might be able to use 2-drug ART for rapid start, but in my own practice, I’m hesitant until we have more studies.

Jason Halperin, MD, MPH Released: November 29, 2021

Download this PDF to share with your patients newly diagnosed with HIV who are considering rapid initiation of ART.

Jason Schafer, PharmD, MPH Released: February 28, 2022

Download this PDF to share with your patients with HIV who are initiating ART and concerned about weight gain.

Michelle S. Cespedes, MD, MS Released: April 26, 2022

In this on-demand recording of a live webinar, expert faculty review key considerations for rapid initiation of ART. Topics include current recommendations and a discussion of the data to support ART options for rapid initiation.

Jason Halperin, MD, MPH Jürgen K. Rockstroh, MD Released: September 29, 2021

Learn key considerations for rapid initiation of ART. Topics include current recommendations and a discussion of the data to support ART options for rapid initiation.

Jason Halperin, MD, MPH Jürgen K. Rockstroh, MD Released: September 29, 2021

In this case example, learn the data and recommendations for the use of NNRTIs in current practice, including key situations where this class could be considered over INSTI-based ART.

Karen Ha, MD Released: December 6, 2021

Learn the data and recommendations for the use of NNRTIs in current practice, including key situations where this class could be considered over INSTI-based ART.

Karen Ha, MD Released: December 13, 2021

Listen as Karen Ha, MD, shares the latest data and recommendations for the use of NNRTIs in current practice, including key situations where this class could be considered over INSTI-based ART.

Karen Ha, MD Released: January 6, 2022

In this case example, learn the data and recommendations for the use of PIs in current practice, including key situations where this class could be considered.

Karen Ha, MD Released: December 17, 2021

Learn the data and recommendations for the use of PIs in current practice, including key situations where this class could be considered

Karen Ha, MD Released: December 27, 2021

Listen as Karen Ha, MD, shares the latest data and recommendations for the use of PIs in current practice, including key situations where this class could be considered.

Karen Ha, MD Released: January 6, 2022

Read a patient’s perspective on the importance of confronting stigma associated with an HIV diagnosis and forming connections with others through volunteer work.

Anonymous Patient Released: January 10, 2022

In this case example, learn the latest data about whether to use tenofovir alafenamide during pregnancy.

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP Released: September 15, 2021

Learn the latest data about whether to use tenofovir alafenamide during pregnancy.

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP Released: September 24, 2021

Listen as Milena Murray, PharmD, MSc, BCIDP, AAHIVP, shares key data and recommendations to support the use of TAF in pregnancy.

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP Released: September 29, 2021

In this on-demand recording of a live webinar, expert faculty review key considerations for the use of ART in pregnancy. Topics include current recommendations and a discussion of the data to support ART options during pregnancy.

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP Jonah Musa, MBBS, MSCI, PhD Released: November 8, 2021

Learn key considerations for the use of ART in older PWH. Topics include current data and recommendations on polypharmacy, drug-drug interactions, drug-disease state interactions, and cardiovascular risk considerations

Jonathan Appelbaum, MD, FACP, AAHIVS Jens D. Lundgren, MD, DMSc Released: November 29, 2021

In this on-demand recording of a live webinar, expert faculty review key considerations for the use of ART in older PWH. Topics include current data and recommendations on polypharmacy, drug–drug interactions, drug–disease state interactions, and cardiovascular risk considerations.

Jonathan Appelbaum, MD, FACP, AAHIVS Jens D. Lundgren, MD, DMSc Released: December 21, 2021

In this case example, learn the latest data about maternal weight gain associated with ART use in pregnancy including pregnancy effects and the role of baseline maternal weight.

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP Released: September 21, 2021

Learn the latest data about maternal weight gain associated with ART use in pregnancy including pregnancy effects and the role of baseline maternal weight.

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP Released: September 27, 2021

Listen as Milena Murray, PharmD, MSc, BCIDP, AAHIVP, shares the latest data on maternal weight gain associated with ART use in pregnancy including pregnancy effects and the role of baseline maternal weight.

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP Released: October 12, 2021

Many patients are receiving BIC/FTC/TAF as an initial ART regimen, but what should you do if these patients become pregnant?

William R. Short, MD, MPH, AAHIVS Released: October 15, 2021

Learn key considerations for the use of ART in pregnancy. Topics include current recommendations and a discussion of the data to support ART options during pregnancy.

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP Jonah Musa, MBBS, MSCI, PhD Released: October 20, 2021

In this case example, learn some of the key considerations for ART management for transgender PWH including providing care within a gender-affirmative care model, considering drug-drug interactions between hormone therapy and ART, and addressing barriers to engagement and retention in care.

Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS Released: April 18, 2022

Learn some of the key considerations for ART management for transgender PWH including providing care within a gender-affirmative care model, considering drug-drug interactions between hormone therapy and ART, and addressing barriers to engagement and retention in care.

Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS Released: April 29, 2022

Listen as Dr Michelle D. Collins-Ogle shares some of the key considerations for ART management for transgender PWH, including providing care within a gender-affirmative care model, considering drug–drug interactions between hormone therapy and ART, and addressing barriers to engagement and retention in care.

Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS Released: May 26, 2022

Download this PDF to share with your patients with HIV who are pregnant or considering pregnancy.

Michelle S. Cespedes, MD, MS Released: March 28, 2022

In this on-demand recording of a live webinar, expert faculty review key renal and hepatic considerations, such as how to choose ART and what to monitor in older PWH.

Jonathan Appelbaum, MD, FACP, AAHIVS Jens D. Lundgren, MD, DMSc Released: February 10, 2022

In this case example, learn some of the key considerations for choosing ART for pediatric patients, including HIV exposed newborns, and children and adolescents infected with HIV.

Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS Released: April 14, 2022

Learn some of the key considerations for choosing ART for pediatric patients including for HIV exposed newborns, and children and adolescents infected with HIV.

Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS Released: April 29, 2022

Listen as Dr Michelle D. Collins-Ogle shares some of the key considerations for choosing ART for pediatric patients, including for HIV-exposed newborns and children and adolescents infected with HIV.

Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS Released: May 26, 2022

Learn key considerations for the use of ART in older PWH. Topics include current data and recommendations on renal impairment and liver disease.

Jonathan Appelbaum, MD, FACP, AAHIVS Jens D. Lundgren, MD, DMSc Released: January 13, 2022

One patient’s journey from HIV diagnosis to undetectable while trying to lose weight.

Anonymous Patient Released: November 29, 2021

One woman’s journey from a late HIV diagnosis to treatment, rehabilitation, and searching for her purpose.

Anonymous Patient Released: December 27, 2021

In this case example, learn the data supporting guideline recommendations about the consequences of suboptimal CD4+ cell count, whether to intensify therapy, switch ART, and more.

William R. Short, MD, MPH, AAHIVS Released: October 15, 2021

Learn the data supporting guideline recommendations about the consequences of suboptimal CD4+ cell count, whether to intensify therapy, switch ART, and more.

William R. Short, MD, MPH, AAHIVS Released: November 3, 2021

Listen as William R. Short, MD, MPH, AAHIVS, discusses the data supporting guideline recommendations about the consequences of suboptimal CD4+ cell count, whether to intensify therapy, switch ART, and more.

William R. Short, MD, MPH, AAHIVS Released: November 19, 2021

Here’s my take on the need for prophylaxis for Pneumocystis jirovecii pneumonia in virologically suppressed patients, including discussion of dosing and choice of regimen when used.

Roger Bedimo, MD, MS, FACP Released: November 23, 2021

Get my take on ART modification to reduce CVD risk in PWH, including discussion of the growing evidence associating certain ARVs with increased CVD risk.

Jens D. Lundgren, MD, DMSc Released: November 29, 2021

Here are my thoughts on how we should approach late-presenting patients and why it is important to get patients with transmissible HIV into care earlier.

Tristan J. Barber, MA, MD, FRCP Released: December 17, 2021

Read a patient’s perspective on the importance of maintaining adherence to antiretroviral therapy through the challenging effects of aging with long-term HIV.

Anonymous Patient Released: January 11, 2022

In this case example, learn the data and recommendations for treating HIV and HCV in patients who are coinfected, including considerations for HCV treatment as prevention and the impact of HCV treatment on the HIV care cascade.

Mark S. Sulkowski, MD Released: January 19, 2022

Treating tuberculosis in a person with HIV can be complicated for both the healthcare professional and the patient. Here’s my take on choosing an ART regimen for people coinfected with tuberculosis and HIV.

Daria Podlekareva, MD, PhD Released: March 7, 2022

Listen as Mark S. Sulkowski, MD, shares the latest data and recommendations for treating HIV and HCV in patients who are coinfected, including considerations for HCV treatment as prevention and the impact of HCV treatment on the HIV care cascade.

Mark S. Sulkowski, MD Released: February 16, 2022

Learn key considerations for the initiation and management of ART in the setting of opportunistic infections. Topics include current data and recommendations for patients with pneumocystis pneumonia, Kaposi’s sarcoma, cytomegalovirus, and cryptococcal meningitis.

Cristina Mussini, MD William R. Short, MD, MPH, AAHIVS Released: March 21, 2022

Learn key considerations for the use of current and future novel therapies including as prevention, initial treatment, switch strategies, and in heavily-treatment experienced patients with HIV.

Cristina Mussini, MD William R. Short, MD, MPH, AAHIVS Released: April 15, 2022

Learn the data and recommendations for treating HIV and HCV in patients who are coinfected, including considerations for HCV treatment as prevention and the impact of HCV treatment on the HIV care cascade.

Mark S. Sulkowski, MD Released: January 26, 2022

Listen as Jason Schafer, PharmD, MPH, shares the latest data and recommendations for using ART in the inpatient setting, including considerations for drug–drug interactions, renal and hepatic dose adjustments, food effects, swallowing difficulties, and the importance of antiretroviral stewardship to avoid errors.

Jason Schafer, PharmD, MPH Released: March 14, 2022

In this case example, learn the data and recommendations for using ART in the inpatient setting including considerations for drug-drug interactions, renal and hepatic dose adjustments, food effects, swallowing difficulties and the importance of antiretroviral stewardship to avoid errors.

Jason Schafer, PharmD, MPH Released: February 7, 2022

Learn the data and recommendations for using ART in the inpatient setting including considerations for drug-drug interactions, renal and hepatic dose adjustments, food effects, swallowing difficulties and the importance of antiretroviral stewardship to avoid errors.

Jason Schafer, PharmD, MPH Released: February 14, 2022

Learn key considerations when choosing ART for patients with coinfections including for patients with HBV/HIV and TB/HIV.

Daria Podlekareva, MD, PhD Mark S. Sulkowski, MD Released: December 29, 2021

In this on-demand recording of a live webinar, expert faculty review key considerations when choosing ART for patients with coinfections including for patients with HBV/HIV and TB/HIV.

Daria Podlekareva, MD, PhD Mark S. Sulkowski, MD Released: January 10, 2022

In this on-demand recording of a live webinar, expert faculty review key considerations for the use of ART in the setting of opportunistic infections. Topics include current data and recommendations for patients with pneumocystis pneumonia, Kaposi sarcoma, cytomegalovirus, and cryptococcal meningitis.

Cristina Mussini, MD William R. Short, MD, MPH, AAHIVS Released: April 5, 2022

In this on-demand recording of a live webinar, expert faculty review key considerations for the use of current and future HIV novel therapies, including as prevention, initial treatment, switch strategies, and in heavily treatment–experienced patients with HIV.

Cristina Mussini, MD William R. Short, MD, MPH, AAHIVS Released: May 2, 2022

For the second time in HIV history, the development of new drugs with novel mechanisms of action and no cross-resistance with any previous antiretroviral drug will allow most highly treatment–experienced patients with resistant HIV to regain virologic suppression.

Josep M. Llibre, MD, PhD Released: October 18, 2021

In this case example, learn the data and recommendations for the use of proviral HIV DNA genotyping to inform ART choice for patients with significant ART experience

John D. Baxter, MD Released: December 29, 2021

Learn the data and recommendations for the use of proviral HIV DNA genotyping to inform ART choice for patients with significant ART experience.

John D. Baxter, MD Released: January 24, 2022

Listen as John D. Baxter, MD, shares the latest data and recommendations for the use of proviral HIV DNA genotyping to inform ART choice for patients with significant ART experience.

John D. Baxter, MD Released: February 1, 2022

In this case example, learn the data and recommendations for initiating ART in a patient with transmitted antiretroviral drug resistance including why many first line ART options can still be considered.

John D. Baxter, MD Released: January 5, 2022

Listen as John D. Baxter, MD, shares the latest data and recommendations for initiating ART in patients with transmitted antiretroviral drug resistance.

John D. Baxter, MD Released: January 25, 2022

Learn data and recommendations for initiating ART in a patient with transmitted antiretroviral drug resistance.

John D. Baxter, MD Released: January 24, 2022

In this on-demand recording of a live webinar, expert faculty review key considerations when choosing ART for patients with virologic failure and resistance, including how to build an optimized background regimen and the data to support the inclusion of novel therapies into ART regimens.

W. David Hardy, MD Josep M. Llibre, MD, PhD Released: December 29, 2021

Learn key considerations when choosing ART for patients with virologic failure and resistance, including how to build an optimized background regimen and the data to support the inclusion of novel therapies into ART regimens.

W. David Hardy, MD Josep M. Llibre, MD, PhD Released: November 29, 2021